We are happy to announce two presentations at the 12th International #mRNA Health Conference in #Boston: Manfred Kraus, Ph.D., Sr. V.P. of R&D at Kernal Bio, will be diving into how Kernal Bio is advancing its in vivo CAR-T approach for potential uses in blood cancers and autoimmune disorders. Don’t miss his poster presentation titled "T Cell Targeted Peripheral LNPs Drive Highly Effective in situ CAR T Cell Programming" on Wednesday, Nov. 13! Cafer Ozdemir, PhD, Co-founder and Director of Convergence Science at Kernal Bio, will be giving a talk about the company and showcasing our computational platform for cell-selective mRNA designs. He'll also present his poster titled "Design Of mRNA With Cell-Specific Differential Translation" on Tuesday, Nov. 12! #mRNA #mrnaconference
Kernal Biologics
生物技术研究
Cambridge,Massachusetts 3,021 位关注者
KernalBio creates mRNA therapies that instruct specific cells on how to make their own medicine
关于我们
Kernal creates mRNA therapies to cure severe diseases including cancer. Our mRNA therapies instruct specific cells on how to make their own drugs. With roots at MIT, Harvard and Big Pharma, our team previously built a successful Biotech company and has deep expertise in mRNA space.
- 网站
-
http://www.kernalbio.com
Kernal Biologics的外部链接
- 所属行业
- 生物技术研究
- 规模
- 11-50 人
- 总部
- Cambridge,Massachusetts
- 类型
- 私人持股
- 创立
- 2016
- 领域
- synthetic biology、RNA design、immunotherapy、covid-19、cancer和mRNA therapy
地点
-
主要
700 Main St
US,Massachusetts,Cambridge,02139
Kernal Biologics员工
-
Manfred Kraus
-
Saeid Akhtari
Founder and Managing Director, HBM Genomics
-
Helen H. Liang, PhD
Founder & Managing Partner of FoundersX Ventures. Featured on WSJ and Business Insider as a Pioneering Tech VC. Board Director. Invited Speaker at…
-
Kou Qin, PhD
Investment Director @ Eisai Innovation | Biotech Venture Capitalist
动态
-
I'm excited to be giving a talk on "Characterization of T-cell targeted CAR #mRNA LNPs" at the 9th CAR-TCR Summit in Boston this September! You can join me at 1.40PM on Day 1 (Wednesday 18th). Learn more here: https://lnkd.in/eKcr9jXa #CARTCR #mRNA CAR-TCR Summit Series Kernal Biologics
-
-
Manfred Kraus, Kernal Biologics’ Sr. VP of R&D will be presenting at the mRNA-Based Therapeutics Summit tomorrow! #mRNASummit #mRNATherapeutics
I’m looking forward to presenting at the 4th mRNA-Based Therapeutics Summit tomorrow July 30th. See my session details in the event program here: https://lnkd.in/gNnuhm4H #mRNASummit #WorldRNA #mRNAVaccines #mRNATherapeutics
-
-
𝐀𝐈 𝐱 𝐁𝐢𝐨 𝐒𝐮𝐦𝐦𝐢𝐭: Kernal Biologics co-founder Yusuf Erkul describes designing mRNA therapies that are selectively delivered to, and translated by, specific cells in the body. He explains the four components that go into getting mRNA to the right location in the body and to be translated in the right cells, and how technology is allowing the company to do this work today. Full video: https://lnkd.in/gK7MVivp BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent
-
I had the pleasure to sit down with Brad Loncar of BiotechTV at the AI x Bio Summit in New York Stock Exchange today. We discussed our cutting-edge work on next generation mRNA LNP therapeutics at Kernal Biologics. Many thanks to the organizers Pablo Lubroth and Amee Kapadia and hosts Decoding Bio Hummingbird Ventures Cantos and NYSE for putting together another great summit this year! Also a big shoutout to the sponsors Bunsen, McKinsey & Company, HSBC, Orrick, Herrington & Sutcliffe LLP and Amazon Web Services (AWS)!
𝐀𝐈 𝐱 𝐁𝐢𝐨 𝐒𝐮𝐦𝐦𝐢𝐭: Kernal Biologics co-founder Yusuf Erkul describes designing mRNA therapies that are selectively delivered to, and translated by, specific cells in the body. He explains the four components that go into getting mRNA to the right location in the body and to be translated in the right cells, and how technology is allowing the company to do this work today. Full video: https://lnkd.in/gK7MVivp BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent
-
𝐀𝐈 𝐱 𝐁𝐢𝐨 𝐒𝐮𝐦𝐦𝐢𝐭: Kernal Biologics co-founder Yusuf Erkul describes designing mRNA therapies that are selectively delivered to, and translated by, specific cells in the body. He explains the four components that go into getting mRNA to the right location in the body and to be translated in the right cells, and how technology is allowing the company to do this work today. Full video: https://lnkd.in/gK7MVivp BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent